BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Temraz S, Mukherji D, Alameddine R, Shamseddine A. Methods of overcoming treatment resistance in colorectal cancer. Crit Rev Oncol Hematol 2014;89:217-30. [PMID: 24075059 DOI: 10.1016/j.critrevonc.2013.08.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Yu X, Li Z, Yu J, Chan MT, Wu WK. MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer. Cell Prolif 2015;48:503-10. [PMID: 26202377 DOI: 10.1111/cpr.12202] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
2 Xie T, Geng J, Wang Y, Wang L, Huang M, Chen J, Zhang K, Xue L, Liu X, Mao X, Chen Y, Wang Q, Dai T, Ren L, Yu H, Wang R, Chen L, Chen C, Chu X. FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10. Oncotarget 2017;8:8574-89. [PMID: 28051999 DOI: 10.18632/oncotarget.14351] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
3 Sun Y, Li G, Zhou Q, Shao D, Lv J, Zhou J. Dual Targeting of Cell Growth and Phagocytosis by Erianin for Human Colorectal Cancer. Drug Des Devel Ther 2020;14:3301-13. [PMID: 32848368 DOI: 10.2147/DDDT.S259006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Ducreux M, Bennouna J, Adenis A, Conroy T, Lièvre A, Portales F, Jeanes J, Li L, Romano A. Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial. Cancer Chemother Pharmacol 2017;79:9-16. [DOI: 10.1007/s00280-016-3193-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
5 Dinparast L, Dastmalchi S. A QSAR Study on the 4-Substituted Coumarins as Potent Tubulin Polymerization Inhibitors. Adv Pharm Bull 2020;10:271-7. [PMID: 32373496 DOI: 10.34172/apb.2020.032] [Reference Citation Analysis]
6 Nijhuis A, Thompson H, Adam J, Parker A, Gammon L, Lewis A, Bundy JG, Soga T, Jalaly A, Propper D. Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. Hum Mol Genet. 2017;26:1552-1564. [PMID: 28207045 DOI: 10.1093/hmg/ddx059] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
7 Dabkeviciene D, Jonusiene V, Zitkute V, Zalyte E, Grigaitis P, Kirveliene V, Sasnauskiene A. The role of interleukin-8 (CXCL8) and CXCR2 in acquired chemoresistance of human colorectal carcinoma cells HCT116. Med Oncol. 2015;32:258. [PMID: 26519257 DOI: 10.1007/s12032-015-0703-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
8 Chen S, Yue T, Huang Z, Zhu J, Bu D, Wang X, Pan Y, Liu Y, Wang P. Inhibition of hydrogen sulfide synthesis reverses acquired resistance to 5-FU through miR-215-5p-EREG/TYMS axis in colon cancer cells. Cancer Lett 2019;466:49-60. [PMID: 31542354 DOI: 10.1016/j.canlet.2019.09.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
9 Mauri G, Gori V, Bonazzina E, Amatu A, Tosi F, Bencardino K, Ruggieri L, Patelli G, Arena S, Bardelli A, Siena S, Sartore-Bianchi A. Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. Cancer Treat Rev 2020;91:102112. [PMID: 33091698 DOI: 10.1016/j.ctrv.2020.102112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Shi X, Zhao W, Yang Y, Wu S, Lv B. Salidroside could enhance the cytotoxic effect of L‑OHP on colorectal cancer cells. Mol Med Rep 2018;17:51-8. [PMID: 29115408 DOI: 10.3892/mmr.2017.7846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
11 Su M, Qin B, Liu F, Chen Y, Zhang R. Andrographolide enhanced 5-fluorouracil-induced antitumor effect in colorectal cancer via inhibition of c-MET pathway. Drug Des Devel Ther 2017;11:3333-41. [PMID: 29200829 DOI: 10.2147/DDDT.S140354] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
12 Moradi Z, Mohammadian M, Saberi H, Ebrahimifar M, Mohammadi Z, Ebrahimpour M, Behrouzkia Z. Anti-cancer effects of chemotherapeutic agent; 17-AAG, in combined with gold nanoparticles and irradiation in human colorectal cancer cells. Daru 2019;27:111-9. [PMID: 30835081 DOI: 10.1007/s40199-019-00251-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
13 Lereclus E, Tout M, Girault A, Baroukh N, Caulet M, Borg C, Bouché O, Ternant D, Paintaud G, Lecomte T, Raoul W. A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen. BMC Cancer 2017;17:220. [PMID: 28347290 DOI: 10.1186/s12885-017-3210-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
14 Zhang Y, Sun L, Sun Y, Chen Y, Wang X, Xu M, Chi P, Xu Z, Lu X. Overexpressed CES2 has prognostic value in CRC and knockdown CES2 reverses L-OHP-resistance in CRC cells by inhibition of the PI3K signaling pathway. Exp Cell Res 2020;389:111856. [PMID: 31981591 DOI: 10.1016/j.yexcr.2020.111856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Huczyński A, Antoszczak M, Kleczewska N, Lewandowska M, Maj E, Stefańska J, Wietrzyk J, Janczak J, Celewicz L. Synthesis and biological activity of salinomycin conjugates with floxuridine. European Journal of Medicinal Chemistry 2015;93:33-41. [DOI: 10.1016/j.ejmech.2015.01.045] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
16 Liu XY, Zheng CB, Wang T, Xu J, Zhang M, Gou LS, Jin L, Qi X, Zeng X, Li H, Qiu S, Zhang P. SPZ1 promotes deregulation of Bim to boost apoptosis resistance in colorectal cancer. Biosci Rep 2020;134:155-67. [PMID: 31934723 DOI: 10.1042/CS20190865] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Dai XY, Zhou BF, Xie YY, Lou J, Li KQ. Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells. Oncol Lett 2018;15:8019-26. [PMID: 29849804 DOI: 10.3892/ol.2018.8332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
18 Li T, Jin X, Dong J, Deng H. Long noncoding RNA ARSR is associated with a poor prognosis in patients with colorectal cancer. J Gene Med 2020;22:e3241. [PMID: 32558022 DOI: 10.1002/jgm.3241] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Sun W, Ge Y, Cui J, Yu Y, Liu B. Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2. Mol Ther Oncolytics 2021;21:87-97. [PMID: 33981825 DOI: 10.1016/j.omto.2021.03.010] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Alcaide J, Delgado M, Legerén M, Jurado JM, Blancas I, Pereda T, López J, Garrido M, Sánchez MJ, García JL, Rueda A. Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases. Oncol Lett 2016;12:3127-34. [PMID: 27899972 DOI: 10.3892/ol.2016.5068] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Lin YM, Chen CI, Hsiang YP, Hsu YC, Cheng KC, Chien PH, Pan HL, Lu CC, Chen YJ. Chrysin Attenuates Cell Viability of Human Colorectal Cancer Cells through Autophagy Induction Unlike 5-Fluorouracil/Oxaliplatin. Int J Mol Sci 2018;19:E1763. [PMID: 29899208 DOI: 10.3390/ijms19061763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
22 Chen SJ, Chung YC, Chang HL, Chang HP, Chou JL, Lin CC, Chen CH, Hsu CP. Synergistic Effect of Combined Treatment with Longan Flower Extract and 5-Fluorouracil on Colorectal Cancer Cells. Nutr Cancer 2020;72:209-17. [PMID: 31179754 DOI: 10.1080/01635581.2019.1622739] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Aryapour H, Dehdab M, Sohraby F, Bargahi A. Prediction of new chromene-based inhibitors of tubulin using structure-based virtual screening and molecular dynamics simulation methods. Computational Biology and Chemistry 2017;71:89-97. [DOI: 10.1016/j.compbiolchem.2017.09.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
24 Gao H, Song X, Kang T, Yan B, Feng L, Gao L, Ai L, Liu X, Yu J, Li H. Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. Onco Targets Ther. 2017;10:205-216. [PMID: 28115855 DOI: 10.2147/ott.s116178] [Cited by in Crossref: 46] [Cited by in F6Publishing: 26] [Article Influence: 9.2] [Reference Citation Analysis]
25 Wang SJ, Cao YF, Yang ZQ, Jiang ZY, Cai B, Guo J, Zhang S, Zhang XL, Gao F. MicroRNA-93-5p increases multidrug resistance in human colorectal carcinoma cells by downregulating cyclin dependent kinase inhibitor 1A gene expression. Oncol Lett 2017;13:722-30. [PMID: 28356951 DOI: 10.3892/ol.2016.5463] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
26 Pham DT, Saelim N, Tiyaboonchai W. Paclitaxel loaded EDC-crosslinked fibroin nanoparticles: a potential approach for colon cancer treatment. Drug Deliv Transl Res 2020;10:413-24. [PMID: 31701488 DOI: 10.1007/s13346-019-00682-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
27 Wen C, Huang L, Chen J, Lin M, Li W, Lu B, Rutnam ZJ, Iwamoto A, Wang Z, Yang X, Liu H. Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells. Int J Oncol 2015;47:1663-71. [PMID: 26397804 DOI: 10.3892/ijo.2015.3166] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
28 Savino S, Gandin V, Hoeschele JD, Marzano C, Natile G, Margiotta N. Dual-acting antitumor Pt( iv ) prodrugs of kiteplatin with dichloroacetate axial ligands. Dalton Trans 2018;47:7144-58. [DOI: 10.1039/c8dt00686e] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
29 Tan Y, Zhang S, Zhu H, Chu Y, Zhou H, Liu D, Huo J. Histone deacetylase 6 selective inhibitor ACY1215 inhibits cell proliferation and enhances the chemotherapeutic effect of 5-fluorouracil in HCT116 cells. Ann Transl Med 2019;7:2. [PMID: 30788349 DOI: 10.21037/atm.2018.11.48] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
30 Li FJ, Hu JH, Ren X, Zhou CM, Liu Q, Zhang YQ. Toad venom: A comprehensive review of chemical constituents, anticancer activities, and mechanisms. Arch Pharm (Weinheim) 2021;354:e2100060. [PMID: 33887066 DOI: 10.1002/ardp.202100060] [Reference Citation Analysis]
31 Al-Qasem A, Al-Howail HA, Al-Swailem M, Al-Mazrou A, Al-Otaibi B, Al-Jammaz I, Al-Khalaf HH, Aboussekhra A. PAC exhibits potent anti-colon cancer properties through targeting cyclin D1 and suppressing epithelial-to-mesenchymal transition. Mol Carcinog 2016;55:233-44. [PMID: 25641341 DOI: 10.1002/mc.22271] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
32 Molins EAG, Jusko WJ. Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells. AAPS J 2018;20:80. [PMID: 29951754 DOI: 10.1208/s12248-018-0235-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
33 Zhang N, Hu X, Du Y, Du J. The role of miRNAs in colorectal cancer progression and chemoradiotherapy. Biomedicine & Pharmacotherapy 2021;134:111099. [DOI: 10.1016/j.biopha.2020.111099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
34 Tong M, Zheng W, Lu X, Ao L, Li X, Guan Q, Cai H, Li M, Yan H, Guo Y, Chi P, Guo Z. Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues. Oncotarget 2015;6:41216-27. [PMID: 26515599 DOI: 10.18632/oncotarget.5649] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
35 Wang W, Guo W, Li L, Fu Z, Liu W, Gao J, Shu Y, Xu Q, Sun Y, Gu Y. Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression. Biochem Pharmacol 2016;121:8-17. [PMID: 27693317 DOI: 10.1016/j.bcp.2016.09.024] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
36 Zhou Z, Chen J, Yao H, Hu H. Fusobacterium and Colorectal Cancer. Front Oncol. 2018;8:371. [PMID: 30374420 DOI: 10.3389/fonc.2018.00371] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 11.8] [Reference Citation Analysis]
37 Lima CF, Costa M, Proença M, Pereira-wilson C. Novel structurally similar chromene derivatives with opposing effects on p53 and apoptosis mechanisms in colorectal HCT116 cancer cells. European Journal of Pharmaceutical Sciences 2015;72:34-45. [DOI: 10.1016/j.ejps.2015.02.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]